JLK제이엘케이

JLK's shares are down sharply over the past year while its trailing losses remain very large against small revenue.

JLK is a Korean medical AI company whose core product is MEDIHUB STROKE, a suite of 12 stroke-related AI solutions, plus cancer analysis tools. Trailing twelve-month revenue to H1 2026 was about ₩2.7B, against an operating loss of about ₩13.7B and a net loss of about ₩15.1B. The share price closed at ₩4,655 on 2026-10-23, roughly 16% lower over one year, with a 52-week range of ₩3,765 to ₩9,210.

What stands out

• Revenue is small relative to losses: TTM operating margin is about -502% and net margin about -555%.
• Revenue jumped 133.9% in 2025 to about ₩3.3B after falling in 2024, but operating losses have stayed above ₩13B in each of the last two years.
• Borrowings of about ₩31.1B exceed cash of about ₩4.9B, and TTM free cash flow was about -₩12.6B.
• The valuation model's base case is ₩121 per share, well below the current price; the bear and bull cases are ₩173 and ₩47, a spread that is hard to read as a clear signal. The model's inputs are not fully described in the data.
• Foreign ownership is low at 1.3%, up from 1.1% about 60 days earlier; 20-day flows show retail net selling of about ₩351M, with foreign and institutional buying.

What to watch

• The next quarterly and annual results, and whether losses narrow relative to revenue.
• Funding needs given the debt-to-equity ratio of about 100% and negative free cash flow; the filings do not state any financing plans.
• Filings for the shareholders' meeting and any follow-up disclosures after the August 2026 extraordinary meeting and independent director changes; no news headlines were available in the data.